Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

Journal of Virology

Volumn 76, Issue 9, 2002, Pages 4634-4642

  Yang, Xinzhen ^a   Lee, Juliette ^a   Mahony, Erin M ^a   Kwong, Peter D ^a   Wyatt, Richard ^a   Sodroski, Joseph ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRITIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HYBRID PROTEIN; IMMUNOGLOBULIN; MEMBRANE PROTEIN; MONOMER; NEUTRALIZING ANTIBODY; PROTEIN 2G12; PROTEIN G1B12; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ARTICLE; BACTERIOPHAGE; CARBOXY TERMINAL SEQUENCE; GENE CONSTRUCT; HUMAN IMMUNODEFICIENCY VIRUS 1; MELTING POINT; MOLECULAR RECOGNITION; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; THERMOSTABILITY; VIRUS ENVELOPE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; PROTEIN CONFORMATION; RECEPTORS, CCR5; RECOMBINANT FUSION PROTEINS; VIRAL PROTEINS;

EID: 0036231093     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.9.4634-4642.2002     Document Type: Article

References (52)

1. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III
2. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
3. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
4. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
5. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
6. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies
7. Why do we not have an HIV vaccine and how can we make one?
8. Efficient neutralization of primary isolates of HIV-1 by a recombinant monoclonal antibody
9. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 (HIV-1) gp41 envelope glycoprotein
10. Core structure of gp41 from the HIV envelope glycoprotein
11. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
12. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant subunit vaccines
13. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
14. Identification of a major co-receptor for primary isolates of HIV-1
15. HIV-1 membrane fusion: Targets of opportunity
16. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
17. + cells is mediated by the chemokine receptor CC-CKR-5
18. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: Requirement of precursor cleavage for glycoprotein incorporation
19. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities
20. Oligomeric structure of the human immunodeficiency virus type I envelope glycoprotein
21. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein
22. Stabilization of human immunodeficiency virus type-1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain
23. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
24. Stabilization of short collagen-like triple helices by protein engineering
25. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41
26. Capture of an early fusion-active conformation of HIV-1 gp41
27. HIV-1 inhibition by a peptide
28. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
29. A trimeric structural domain of the HIV-1 transmembrane glycoprotein
30. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
31. Binding of the human retrovirus HTLV- III/LAV/ARV/ HIV to the CD4 (T4) molecule: Conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry
32. Enhanced expression, native purification and characterization of CCR5, a principal HIV-1 coreceptor
33. Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin
34. Crystal structure of SIV matrix antigen and implications for virus assembly
35. Characterization of envelope and core gene products of HTLV-III with sera from AIDS patients
36. Protein design of an HIV-1 entry inhibitor
37. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
38. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120
39. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
40. Atomic structure of a thermostable subdomain of HIV-1 gp41
41. Structure of bacteriophage T4 fibritin: A segmented coiled coil and the role of the C-terminal domain
42. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
43. Human monoclonal antibody 2G12 defines as distrinctive neutralization activity against primary human immunodeficiency virus type 1 envelope
44. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp16O
45. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope
46. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene
47. Atomic structure of the ectodomain from HIV-1 gp41
48. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
49. HIV-1 MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals
50. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution
51. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
52. Improved elicitation of neutralization antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoproteins